Navigation Links
New Pharmaxis Board Appointment

SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of the U.S. life science investment manager Richard van den Broek to its Board of Directors.

Mr van den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. HSMR Advisors has held a position on the Pharmaxis share register since 2005.

During his career Mr van den Broek has worked on both the buy and sell side of the funds management industry holding senior positions at Cooper Hill Partners, Hambrecht & Quist (H&Q), Merrill Lynch and Oppenheimer & Co.

"Richard has been an engaged investor for a number of years and has great insight into the life science industry and the U.S. capital markets," said Pharmaxis Chief Executive Officer, Dr Alan Robertson. "Our shareholders will benefit from his skills and experience."

In accepting the board position Mr van den Broek said: "Pharmaxis holds enormous promise and I look forward to being part of an exciting company at a key point in its development as a global provider of innovative medicines.

I am very much looking forward to working with the Pharmaxis Board."

Mr van den Broek is a Chartered Financial Analyst, and is a graduate of Harvard University.

    For information on all Pharmaxis Board members, go to:

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.


     Alan Robertson -- Chief Executive Officer
     Tel:   +61-2-9454-7200

     Felicity Moffatt
     Tel:   +61-418-677-701

    United States:
     Brandon Lewis, Trout Group
     Tel:   +1-646-378-2915

SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmaxis Investor Conference Call
2. Pharmaxis Appoints French Distributor for Aridol(TM)
3. Pharmaxis Builds Senior Management Team
4. Pharmaxis Investor Conference Call
5. Pharmaxis Aridol Approved for Sale in Switzerland
6. Pharmaxis Investor Conference Call
7. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
8. New Pharmaxis Board Appointment
9. Pharmaxis Aridol Authorised for Sale in Germany
10. Pharmaxis First Steps into China
11. Pharmaxis to Apply to Market Bronchitol in Australia
Post Your Comments:
(Date:12/1/2015)... 2015 Dr. Harry Lander , President of Regen, ... Chief Science Officer and recruits five distinguished ... , President of Regen, expands his role to include ... five distinguished scientists to join advisory team --> ... role to include serving as Chief Science ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for the ... in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss new ...
(Date:11/30/2015)...  An interventional radiology technique shows promise for helping morbidly ... a study being presented today at the annual meeting of ... (RSNA). --> --> ... radiologists as a way to stop bleeding in emergency situations, ... of treating obesity is new. Mubin Syed , ...
(Date:11/30/2015)... HOLLISTON, Mass. , Nov. 30, 2015 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered ... has received written notification from The NASDAQ Stock ... minimum bid price requirements. The letter noted that ... of HART,s common stock having exceeded $1.00 per ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
(Date:10/26/2015)... , Oct. 26, 2015  Delta ID Inc., ... authentication to mobile and PC devices, announced its ActiveIRIS® ... the arrows NX F-02H launched by NTT DOCOMO, INC ... F-02H is the second smartphone to include iris recognition ... in ARROWS NX F-04G in May 2015, world,s first ...
Breaking Biology News(10 mins):